| Revenue growth | 5.6% YoY for Q4FY26; 6.1% for full year FY26. |
|---|---|
| Margins | EBITDA margin at 20.3% in Q4FY26 vs 21.4% in Q4FY25. |
| Demand visibility | Strong Europe performance; stable US base business despite seasonality. |
Growth
FY26 revenue grew 6.1% YoY to ₹33,653 Cr; Europe grew 23.4% and Growth Markets 10% in FY26.
Outlook
Targets 7-8 marketed biosimilars in EU/UK/Canada by 2030; USD 150-175 Mn CAPEX for TheraNym Unit 2.
Risks
USA revenue declined 13% YoY in Q4 due to seasonality and lower transient product sales.
Earnings Call filed with NSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,712.00
- Market cap
- ₹99,433 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.2×Sector 50.4×
- Promoter holding
- 51.88%+0.06% QoQ
- FII holding
- 16.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Regulatory Approval
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma Acquisition Worth ₹9.47 Cr
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
- Value
- ₹9.47 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
- Value
- ₹9.50 Cr
Aurobindo Pharma Business Update
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma Earnings Call Transcript: Key Takeaways
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
- Call
- Guides 10% growth
Aurobindo Pharma Investor Presentation: Key Takeaways
Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.